Molecular markers are useful in dissection of this heterogeneous group of AML patients into prognostically different subgroups.   7  About 60% of adult CN-AML have a mutation in exon 12 of NPM1 gene.   1  This mutation is specific for malignant clone and potentially is a good marker of MRD more than other markers i.e. WT1 and FLT3-ITD.   3  In this retrospective study, we set up a NPM1 quantitative test and then, AML patients carrying NPM1mut were followed-up for MRD monitoring. This evidence concerns the gene NPM1 and acute myeloid leukemia.